Baird served as the sole book-running manager in this offering
AboutExact Sciences Corp. (“Exact Sciences” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 3,593,750 shares of common stock at a price of $8.00 per share, generating gross proceeds of approximately $28.75 million. The Company intends to use the net proceeds from the offering for general corporate and working capital purposes, including for product development and in furtherance of the Company’s efforts to obtain FDA clearance of its stool-based DNA (sDNA) colorectal cancer screening product and product commercialization activities.
Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. The Company’s primary goal is to become the market leader for a patient-friendly diagnostic screening product for the early detection of colorectal pre-cancer and cancer and is focused on seeking FDA approval for its Cologuard test.
For additional information about this transaction, please contact:
- December 2011
- Exact Sciences Corporation
- Target Location
- North America